BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Sleen Y, Sandovici M, Abdulahad WH, Bijzet J, van der Geest KSM, Boots AMH, Brouwer E. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford) 2019:kez034. [PMID: 30805622 DOI: 10.1093/rheumatology/kez034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Farina N, Tomelleri A, Campochiaro C, Dagna L. Giant cell arteritis: Update on clinical manifestations, diagnosis, and management. Eur J Intern Med 2023;107:17-26. [PMID: 36344353 DOI: 10.1016/j.ejim.2022.10.025] [Reference Citation Analysis]
2 Stamatis P, Turesson C, Michailidou D, Mohammad AJ. Pathogenesis of giant cell arteritis with focus on cellular populations. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1058600] [Reference Citation Analysis]
3 Gernert M, Schmalzing M, Tony H, Strunz P, Schwaneck EC, Fröhlich M. Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. Arthritis Res Ther 2022;24. [DOI: 10.1186/s13075-022-02887-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rizzo C, La Barbera L, Miceli G, Tuttolomondo A, Guggino G. The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.933161] [Reference Citation Analysis]
5 van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, Heeringa P, Brouwer E, Jiemy WF. Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Front Med 2022;9:902155. [DOI: 10.3389/fmed.2022.902155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bond M, Tomelleri A, Buttgereit F, Matteson EL, Dejaco C. Looking ahead: giant-cell arteritis in 10 years time. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210963. [DOI: 10.1177/1759720x221096366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 van Sleen Y, Therkildsen P, Nielsen BD, van der Geest KSM, Hansen I, Heeringa P, Posthumus MD, Sandovici M, Toonen EJM, Zijlstra J, Boots AMH, Hauge EM, Brouwer E. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. Arthritis Res Ther 2022;24:65. [PMID: 35255968 DOI: 10.1186/s13075-022-02754-5] [Reference Citation Analysis]
8 Kuret T, Frank-bertoncelj M, Lakota K, Žigon P, Thallinger GG, Kopitar AN, Čučnik S, Tomšič M, Hočevar A, Sodin-šemrl S. From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. Front Med 2022;8:827095. [DOI: 10.3389/fmed.2021.827095] [Reference Citation Analysis]
9 Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, Espígol-Frigolé G, Ríos-Garcés R, Marco-Hernández J, Denuc A, Kamberovic F, Pérez-Galán P, Joseph A, D'Andrea A, Bondensgaard K, Cid MC, Paolini JF. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2022:annrheumdis-2021-220873. [PMID: 35045965 DOI: 10.1136/annrheumdis-2021-220873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 de Souza AWS, de Melo Cruvinel W, Andrade LEC. Targeting macrophages in systemic diseases. Macrophages in the Human Body 2022. [DOI: 10.1016/b978-0-12-821385-8.00012-3] [Reference Citation Analysis]
11 Tomelleri A, van der Geest KSM, Sebastian A, van Sleen Y, Schmidt WA, Dejaco C, Dasgupta B. Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. The Lancet Rheumatology 2021;3:e886-95. [DOI: 10.1016/s2665-9913(21)00277-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Esen I, Jiemy WF, van Sleen Y, van der Geest KSM, Sandovici M, Heeringa P, Boots AMH, Brouwer E. Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. J Clin Med 2021;10:4958. [PMID: 34768479 DOI: 10.3390/jcm10214958] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
13 Yang N, Zhao Y, Wu X, Zhang N, Song H, Wei W, Liu ML. Recent advances in Extracellular Vesicles and their involvements in vasculitis. Free Radic Biol Med 2021;171:203-18. [PMID: 33951487 DOI: 10.1016/j.freeradbiomed.2021.04.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Aierken X, Zhu Q, Wu T, Liu SS, Cao YY, Cai XT, Aihemaiti A, Bi Y, Yang S, Zhang W, Li N. Increased Urinary CD163 Levels in Systemic Vasculitis with Renal Involvement. Biomed Res Int 2021;2021:6637235. [PMID: 33997033 DOI: 10.1155/2021/6637235] [Reference Citation Analysis]
15 Ahn SS, Yoon T, Park YB, Prendecki M, Bhangal G, McAdoo SP, Lee SW. Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. Arthritis Res Ther 2021;23:77. [PMID: 33685523 DOI: 10.1186/s13075-021-02467-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Innate and Adaptive Immunity in Giant Cell Arteritis. Front Immunol 2020;11:621098. [PMID: 33717054 DOI: 10.3389/fimmu.2020.621098] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
17 Sorić Hosman I, Kos I, Lamot L. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. Front Immunol 2020;11:631299. [PMID: 33679725 DOI: 10.3389/fimmu.2020.631299] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
18 Tombetti E, Hysa E, Mason JC, Cimmino MA, Camellino D. Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides. Curr Rheumatol Rep 2021;23:17. [PMID: 33569633 DOI: 10.1007/s11926-021-00980-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
19 Conticini E, Sota J, Falsetti P, Baldi C, Bardelli M, Bellisai F, Tosi GM, Frediani B, Cantarini L. The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis. Mediators Inflamm 2020;2020:3203241. [PMID: 33061825 DOI: 10.1155/2020/3203241] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Wipfler-Freißmuth E, Dejaco C, Both M. [Long-term complications, monitoring and interventional treatment of large vessel vasculitis]. Z Rheumatol 2020;79:523-31. [PMID: 32430565 DOI: 10.1007/s00393-020-00807-1] [Reference Citation Analysis]
21 Jiemy WF, van Sleen Y, van der Geest KS, Ten Berge HA, Abdulahad WH, Sandovici M, Boots AM, Heeringa P, Brouwer E. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. Clin Transl Immunology 2020;9:e1164. [PMID: 32884747 DOI: 10.1002/cti2.1164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
22 Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol 2020;16:481-95. [DOI: 10.1038/s41584-020-0458-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
23 Dos Santos JP, Artigiani Neto R, Mangueira CLP, Filippi RZ, Gutierrez PS, Westra J, Brouwer E, de Souza AWS. Associations between clinical features and therapy with macrophage subpopulations and T cells in inflammatory lesions in the aorta from patients with Takayasu arteritis. Clin Exp Immunol 2020;202:384-93. [PMID: 32639582 DOI: 10.1111/cei.13489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sun Y, Kong X, Cui X, Dai X, Ma L, Chen H, Chen R, Lv P, Lin J, Huang Q, Jin X, Jiang L. The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. Clin Rheumatol 2020;39:3417-25. [DOI: 10.1007/s10067-020-05066-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
25 van Sleen Y, Boots AMH, Abdulahad WH, Bijzet J, Sandovici M, van der Geest KSM, Brouwer E. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology (Oxford) 2020;59:176-84. [PMID: 31292652 DOI: 10.1093/rheumatology/kez261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
26 van Sleen Y, Graver JC, Abdulahad WH, van der Geest KSM, Boots AMH, Sandovici M, Brouwer E. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. Front Immunol 2019;10:1981. [PMID: 31507597 DOI: 10.3389/fimmu.2019.01981] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
27 Eswaramoorthy SD, Dhiman N, Korra G, Oranges CM, Schaefer DJ, Rath SN, Madduri S. Isogenic-induced endothelial cells enhance osteogenic differentiation of mesenchymal stem cells on silk fibroin scaffold. Regenerative Medicine 2019;14:647-61. [DOI: 10.2217/rme-2018-0166] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]